
A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India's largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries'.
The order this company entered each market — oldest to newest
Sign up to see the full signal feed
How Alkem Laboratories Ltd.'s international expansion compares to its competitors
Bars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
Alkem Laboratories Ltd.You | 0 | 0 | 0% | 0 | 32 |
Assistant Manager - Admin/Facility Management
View postingMumbai, Maharashtra, India · 3d ago
Human Resource Business Partner
View postingMumbai, Maharashtra, India · last wk.
Product Manager - International Business
View postingNavi Mumbai, Maharashtra, India · last wk.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Indian pharma market grew 9.9% YoY in November, driven by new launches and price increases. Most therapies showed healthy growth, with derma leading at 15.8%.
Key stocks to watch include Tata Power, Lupin, RVNL, NLC India, ICICI Prudential Life, and Alkem Labs. Tata Power reported increased profits, while Lupin clarified FDA approval status for a generic HIV drug.
Over 230 companies, including LIC, NHPC, Ola Electric, Mazagon Dock, Delhivery, and M&M, will report Q3 earnings on February 7, 2025.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Alkem Laboratories Ltd.'s business, markets, and growth signals.

© 2026 Pubrio. All rights reserved.